Showing results (1-10 of 14) with videos related to

Sort By:
Pageof 2
Schizophrenia Research|November 5, 2002
Clozapine-induced weight gain predicts improvement in psychopathologyHerbert Y Meltzer, Edward Perry, Karuna Jayathilake
Frontiers in Microbiology|September 28, 2020
Respiratory Microbial Co-infection With SARS-CoV-2Bill W Massey, Karuna Jayathilake, Herbert Y Meltzer
Psychiatry Research|August 2, 2011
Prediction of long-term metabolic effects of olanzapine and risperidone treatment from baseline body mass index in schizophrenia and bipolar disorderWilliam Victor Bobo, Stefania Bonaccorso, Karuna Jayathilake, et al.
Human Psychopharmacology|June 25, 2009
Melperone, an aytpical antipsychotic drug with clozapine-like effect on plasma prolactin: contrast with typical neurolepticsWilliam V Bobo, Karuna Jayathilake, Myung A Lee, et al.
Psychiatry Research|March 5, 2010
Changes in weight and body mass index during treatment with melperone, clozapine and typical neurolepticsWilliam V Bobo, Karuna Jayathilake, Myung A Lee, et al.
Psychiatry Research|February 5, 2015
Decreased serotonin2C receptor responses in male patients with schizophreniaMyung Ae Lee, Karuna Jayathilake, Min Young Sim, et al.
The Journal of Clinical Psychiatry|August 5, 2011
A 12-month randomized, open-label study of the metabolic effects of olanzapine and risperidone in psychotic patients: influence of valproic acid augmentationHerbert Y Meltzer, Stefania Bonaccorso, William V Bobo, et al.
Psychiatry Research|April 10, 2010
A randomized trial comparing clozapine and typical neuroleptic drugs in non-treatment-resistant schizophreniaHerbert Y Meltzer, William V Bobo, Myung A Lee, et al.
Schizophrenia Research|June 7, 2011
The effect of adjunctive armodafinil on cognitive performance and psychopathology in antipsychotic-treated patients with schizophrenia/schizoaffective disorder: a randomized, double-blind, placebo-controlled trialWilliam V Bobo, Neil D Woodward, Min Young Sim, et al.
Journal of Psychopharmacology (Oxford, England)|January 12, 2012
Comparative effectiveness of switching antipsychotic drug treatment to aripiprazole or ziprasidone for improving metabolic profile and atherogenic dyslipidemia: a 12-month, prospective, open-label studyYuejin Chen, William V Bobo, Kara Watts, et al.
Pageof 2